Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT01118845 is registered in ClinicalTrials.gov with SymBio Pharmaceuticals as lead sponsor.

NCT NCT01118845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01118845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Lead sponsor
SymBio Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2010
Completion date
October 31, 2011
Enrollment
63 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse, mantle cell lymphoma, lymphoma, follicular lymphoma, large b-cell, diffuse, lymphoma, large cell, non-hodgkin's lymphoma